Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (not Insight Molecular Diagnostics Inc.) on March 4, 2025. The filing details executive compensation adjustments, equity grants, and a senior management promotion effective March 10, 2025.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on personnel compensation and equity awards.
Material Changes and Executive Actions
Executive Salary Increases
- Joshua Riggs (CEO): Annual base salary increased from $400,000 to $420,000.
- Andrea James (CFO): Annual base salary increased from $325,000 to $341,250.
- Ekkehard Schütz (CSO): Annual base salary increased from $378,025 to $396,926.
Equity and Bonus Awards
- CFO Bonus: Andrea James received a one-time bonus of $25,000 (cash or RSUs) for achievements since June 2024.
- Executive RSU Grants (March 9, 2025):
- Joshua Riggs: $600,000 in RSUs (max 200,000 units), vesting 25% annually over 4 years.
- Andrea James: $360,000 in RSUs (max 120,000 units), vesting 25% annually over 4 years.
- Ekkehard Schütz: $360,000 in RSUs (max 120,000 units), vesting 25% annually over 4 years.
Promotion of James Liu
James Liu was promoted to Vice President Accounting, Controller, Treasurer, and Principal Accounting Officer.
- Compensation: Annual salary of $225,000 with a target bonus of 35%.
- Equity: One-time grant of $60,000 in RSUs (vesting 33% annually over 3 years) and 10,000 stock options (vesting 33% after one year, remainder monthly).
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks. It notes that all equity grants are contingent on the release of financial results for the quarter and fiscal year ended December 31, 2024, to determine the grant date and exercise price.
Investor Verification Checklist
- Verify the exact grant date and share count for the RSU and option awards once Q4 2024 financial results are released.
- Confirm the total dilution impact of the new equity grants on outstanding share count.
- Review the company's cash position to ensure liquidity for the $25,000 cash bonus option and increased annual salary obligations.
- Check for any related party transactions involving the newly promoted officers, though the filing states none exist.